Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.520
+0.050 (3.40%)
At close: Jun 6, 2025, 4:00 PM
1.480
-0.040 (-2.63%)
After-hours: Jun 6, 2025, 7:40 PM EDT

Company Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.

Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies.

It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

The company’s product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies.

Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber.

The company was incorporated in 2014 and is headquartered in New York, New York.

Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals logo
Country United States
Founded 2014
IPO Date Apr 3, 2020
Industry Biotechnology
Sector Healthcare
Employees 166
CEO Julie Eastland

Contact Details

Address:
1359 Broadway, Suite 1710
New York, New York 10018
United States
Phone 212 433 3791
Website zentalis.com

Stock Details

Ticker Symbol ZNTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001725160
CUSIP Number 98943L107
ISIN Number US98943L1070
Employer ID 82-3607803
SIC Code 2834

Key Executives

Name Position
Julie M. Eastland M.B.A. Chief Executive Officer, President and Director
Andrea Paul J.D. Chief Legal Officer and Corporate Secretary
Vincent A. Vultaggio SVice President of Finance and Principal Accounting Officer
Wendy Chang Chief People Officer
Kimberly Freeman Chief Strategy Officer
Dr. Ingmar Bruns M.D., Ph.D. Chief Medical Officer
Haibo Wang Chief Business Officer

Latest SEC Filings

Date Type Title
Jun 2, 2025 8-K Current Report
May 23, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 20, 2025 8-K Current Report
May 14, 2025 S-8 Securities to be offered to employees in employee benefit plans
May 14, 2025 10-Q Quarterly Report
May 14, 2025 8-K Current Report
May 14, 2025 SCHEDULE 13G/A Filing
May 13, 2025 SCHEDULE 13G/A Filing
Apr 30, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025 DEF 14A Other definitive proxy statements